Evidence map›Paper›PMID 40108430›Full record

ArticlePediatric research2025

School-age child neurodevelopment following antenatal Zika virus exposure.

Sarah B Mulkey, Regan Andringa-Seed, Elizabeth Corn, Meagan E Williams, Margarita Arroyave-Wessel, Robert H Podolsky, Colleen Peyton, Michael E Msall, Carlos Cure, Madison M Berl

Registry-linked trialAbstract read
In one paragraph

Article in Pediatric research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04398901 (Developmental Outcome After In Utero ZIKV Exposure in Children Without Congenital Zika Syndrome), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04398901 enrolling by invitationnot on this map

Developmental Outcome After In Utero ZIKV Exposure in Children Without Congenital Zika Syndrome

TypeobservationalSponsorChildren's National Research InstituteRan2020 to 2025Enrolled204ConditionsZika Virus, Congenital Zika Syndrome, Congenital Infection, Child DevelopmentArmsNeurodevelopmental assessments
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sarah B MulkeyZickler Family Prenatal Pediatrics Institute, Children's National Hospital, Washington, DC, USA. sbmulkey@childrensnational.org.ORCID http://orcid.org/0000-0002-8084-526X
Regan Andringa-SeedZickler Family Prenatal Pediatrics Institute, Children's National Hospital, Washington, DC, USA.
Elizabeth CornZickler Family Prenatal Pediatrics Institute, Children's National Hospital, Washington, DC, USA.
Meagan E WilliamsZickler Family Prenatal Pediatrics Institute, Children's National Hospital, Washington, DC, USA.
Margarita Arroyave-WesselZickler Family Prenatal Pediatrics Institute, Children's National Hospital, Washington, DC, USA.
Robert H PodolskyDivision of Biostatistics and Study Methodology, Children's National Hospital, Washington, DC, USA.
Colleen PeytonDepartment of Physical Therapy and Human Movement Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Michael E MsallKennedy Research Center on Intellectual and Neurodevelopmental Disabilities, University of Chicago Medicine, Chicago, IL, USA.
Carlos CureBIOMELab, Barranquilla, Atlántico, Colombia.
Madison M BerlDepartment of Pediatrics, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.

Funding

Neurobehavioral Evaluation CoreP50HD105328 · NICHD · CHILDREN'S RESEARCH INSTITUTE · PI KENWORTHY, LAUREN · 2021 to 2025
$6.9M
Childhood Outcome After In Utero ZIKV ExposureR01HD102445 · NICHD · CHILDREN'S RESEARCH INSTITUTE · PI MULKEY, SARAH BETH · 2020 to 2024
$3.6M
NICHD NIH HHS P50 HD105328NICHD NIH HHS R01 HD102445
6 · The paper itself

Abstract

backgroundChildren exposed antenatally to Zika virus (ZIKV) during the 2015-2016 epidemic are now in school; little is known about their neurodevelopment at this age. The objective was to evaluate neurodevelopment of ZIKV-exposed Colombian children compared to non-exposed controls at ages 5-6.

methodsIn total, 48 normocephalic children with antenatal ZIKV exposure (Cases) were recruited for a longitudinal cohort study in Atlántico, Colombia. Two age-matched control groups of 118 non-ZIKV-exposed children were recruited from same communities as Cases: 63 born before ZIKV epidemic but experienced COVID-19-related school entry delays, and 55 born post-ZIKV epidemic but started school on time. Multi-domain neurodevelopment was assessed at 5-6 years using standardized measures. Standard regression and proportional odds models were used to compare outcomes. P values were adjusted using the Benjamini-Hochberg false discovery rate (FDR) (p < 0.05).

resultsThere were no differences in age at assessment between groups. Case Full-Scale IQ scores were lower than both control groups (p = 0.002), driven by visual reasoning (p < 0.001). Controls with school entry delay had more executive control problems and lower adaptive functioning skills than Cases and Controls without school entry delay.

conclusionsZIKV-exposed children have lower cognitive performance compared to controls. Early childhood experiences can affect pediatric outcomes research. IMPACT: Normocephalic ZIKV-exposed children have lower full-scale IQ than their unexposed peers from the same communities. Normocephalic children with antenatal ZIKV exposure have differences in neurodevelopment that can impact them long-term. There is a need for continued follow-up of children with antenatal ZIKV exposure to determine long-term effects on higher-order areas of cognitive function.

Indexed as

Child DevelopmentPregnancy Complications, InfectiousPrenatal Exposure Delayed EffectsZika VirusZika Virus InfectionCase-Control StudiesChildChild, PreschoolColombiaCOVID-19FemaleHumansLongitudinal StudiesMaleNeurodevelopmental DisordersPregnancy

Identifiers

PMID40108430
PMCPMC12273634

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.